Verition Fund Management LLC Purchases Shares of 15,279 GRIFOLS S A/S (GRFS)

Verition Fund Management LLC purchased a new stake in GRIFOLS S A/S (NASDAQ:GRFS) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,279 shares of the biotechnology company’s stock, valued at approximately $324,000.

Other hedge funds have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its position in GRIFOLS S A/S by 14.9% during the first quarter. PNC Financial Services Group Inc. now owns 20,428 shares of the biotechnology company’s stock worth $433,000 after purchasing an additional 2,656 shares during the period. ETRADE Capital Management LLC lifted its position in GRIFOLS S A/S by 16.9% during the first quarter. ETRADE Capital Management LLC now owns 20,010 shares of the biotechnology company’s stock worth $424,000 after purchasing an additional 2,892 shares during the period. First Republic Investment Management Inc. lifted its position in GRIFOLS S A/S by 35.0% during the first quarter. First Republic Investment Management Inc. now owns 12,892 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 3,340 shares during the period. Blair William & Co. IL lifted its position in GRIFOLS S A/S by 9.9% during the first quarter. Blair William & Co. IL now owns 38,960 shares of the biotechnology company’s stock worth $826,000 after purchasing an additional 3,499 shares during the period. Finally, Dean Capital Investments Management LLC lifted its position in GRIFOLS S A/S by 40.9% during the first quarter. Dean Capital Investments Management LLC now owns 13,126 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 3,808 shares during the period. Institutional investors and hedge funds own 21.65% of the company’s stock.

Several equities research analysts recently weighed in on the stock. BidaskClub cut shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research raised shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Friday, June 22nd. JPMorgan Chase & Co. cut shares of GRIFOLS S A/S from an “overweight” rating to a “neutral” rating in a research report on Wednesday, June 13th. Finally, HSBC raised shares of GRIFOLS S A/S from a “reduce” rating to a “hold” rating in a research report on Wednesday, March 14th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $22.50.

GRIFOLS S A/S opened at $21.30 on Friday, MarketBeat Ratings reports. The stock has a market capitalization of $14.68 billion, a PE ratio of 19.03, a P/E/G ratio of 1.44 and a beta of 1.24. The company has a debt-to-equity ratio of 1.57, a current ratio of 3.13 and a quick ratio of 1.36. GRIFOLS S A/S has a 12 month low of $19.92 and a 12 month high of $25.18.

The business also recently announced a special dividend, which was paid on Tuesday, June 12th. Stockholders of record on Monday, June 4th were issued a $0.0125 dividend. The ex-dividend date was Friday, June 1st. This represents a dividend yield of 2.15%. GRIFOLS S A/S’s dividend payout ratio (DPR) is currently 35.45%.

GRIFOLS S A/S Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply